Details of the Drug

General Information of Drug (ID: DMU72KL)

Drug Name

ICP-022

Synonyms

Orelabrutinib; 1655504-04-3; UNII-WJA5UO9E10; WJA5UO9E10; 4-yl]pyridine-3-carboxamide; ICP022; 2-(4-phenoxyphenyl)-6-[1-(prop-2-enoyl)piperidin-; 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide; Orelabrutinib [INN]; orelabrutinib (proposed INN); SCHEMBL16597834; US9951056, Example 3; GTPL10629; BDBM389631; EX-A3442; NSC826039; s9600; NSC-826039; example 3 [WO2015048662A2]; DB-091042; HY-129390; CS-0105163; 2-(4-phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide; 3-Pyridinecarboxamide, 6-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-; 6-(1-(1-Oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-3-pyridinecarboxamide

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 3	[1]
Small lymphocytic lymphoma	2A82.0	Phase 3	[1]
Diffuse large B-cell lymphoma	2A81	Phase 2	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

427.5

Logarithm of the Partition Coefficient (xlogp)

3.6

Rotatable Bond Count (rotbonds)

6

Hydrogen Bond Donor Count (hbonddonor)

1

Hydrogen Bond Acceptor Count (hbondacc)

4

Chemical Identifiers

Formula: C26H25N3O3
IUPAC Name: 2-(4-phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide
Canonical SMILES: C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C(C=C3)OC4=CC=CC=C4
InChI: InChI=1S/C26H25N3O3/c1-2-24(30)29-16-14-18(15-17-29)23-13-12-22(26(27)31)25(28-23)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-13,18H,1,14-17H2,(H2,27,31)
InChIKey: MZPVEMOYADUARK-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 91667513
CAS Number: 1655504-04-3
UNII: WJA5UO9E10
DrugBank ID: DB16272
TTD ID: DUTJ12

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase BTK (ATK)	TTGM6VW	BTK_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Chronic lymphocytic leukaemia

ICD Disease Classification

2A82.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Tyrosine-protein kinase BTK (ATK)	DTT	BTK	3.54E-01	0.24	0.56

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04578613) ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT04438005) A Study of ICP-022 in Patients With R/R DLBCL (DLBCL). U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of InnoCare Pharma.